Chronic Kidney Disease: key endpoint results by drug

The key endpoints of Chronic Kidney Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Chronic Kidney Disease page.

Kidney composite outcome

Kidney composite outcome in Chronic Kidney Disease: 3 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Atrasentan6%7.9%−1.9n 1325NCT01858532 Phase 3, primary
Dapagliflozin6.6%11.3%−4.7n 2152NCT03036150 Phase 3, secondary
Empagliflozin6.1%8.1%−210 mg · n 3304NCT03594110 Phase 3, secondary

Drugs checked with no result here: 33 not reported, 21 trial running, 19 not posted.

UACR, % change

UACR, % change in Chronic Kidney Disease: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Balcinrenone-58.0%230.3%−288.4150 mg + 10 mg · wk 12 · n 25NCT04595370 Phase 2, primary
Canagliflozin0.6%1.2%−0.6100mg · wk 104 · n 124NCT03436693 Phase 3, secondary
Dapagliflozin-22.4%-1.8%−20.610 mg · wk 24 · n 140NCT02547935 Phase 2/3, primary
Empagliflozin-39.1%-2.6%−36.510 mg · wk 14 · n 61NCT05182840 Phase 2, primary
Sotagliflozin (Inpefa)-48.1%-18.7%−29.4400 mg · wk 26 · n 264NCT03242252 Phase 3, secondary
Vicadrostat-38.5%-6.4%−32.120 mg · wk 14 · n 121NCT05182840 Phase 2, primary

Drugs checked with no result here: 32 not reported, 19 trial running, 19 not posted.

eGFR slope

eGFR slope in Chronic Kidney Disease: 2 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Roxadustat-2.6-3.2+0.6n 389NCT01887600 Phase 3, secondary
Tolvaptan-2.3-3.6+1.3wk 61 · n 668NCT02160145 Phase 3, primary

Drugs checked with no result here: 32 not reported, 21 trial running, 21 not posted.

Haemoglobin, change

Haemoglobin, change in Chronic Kidney Disease: 5 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Desidustat1.9a1.8 (darbepoetin)——NCT04012957 Phase 3, primary
Ferric derisomaltose1.21.1 (Iron Sucrose)—wk 8 · n 1027NCT02940860 Phase 3, primary
Pegmolesatide (HS-20039)0.1a-0.2 (epoetin alfa)——NCT03902691 Phase 3, primary
Roxadustat20.2+1.8wk 52 · n 616NCT01750190 Phase 3, primary
Vadadustat1.41.4 (Darbepoetin Alfa)—n 879NCT02648347 Phase 3, primary

Drugs checked with no result here: 33 not reported, 21 trial running, 17 not posted.

  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 76 approved or late-stage drugs with a featured trial in Chronic Kidney Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.